Worth reading
28Immaterial
0–100. This measures how worthwhile something is to read, not how good or bad the company is.Direction
Mixed performance
Direction inferred from the company’s description.Scale
70
¥ millionWording
Avoiding a definitive answer
How definitive the wording is.Contents of this document
Supplementary materials to the earnings summaryThird quarter of the fiscal year ending December 20261 item taken from the company’s own explanation
Financial Results Figures (The key points of this material are explained below)
Net Sales¥346 million
Operating profit¥-676 million
Net income¥-680 million
Selling, general and administrative expenses¥511 million
Full-year earnings forecast
Product Sales Revenue
¥350 million
Cost of Product Sales
¥190 million
What the company explained in this material
New initiatives
- Transfer of the Sancuso® sales structure to MAAB Pharma Limited and product shipments
- Initiatives focused on licensing Chinese manufacturing rights to MAAB and local production
- Commencement of supply to Daiichi Sankyo Brasil for the sale of episil® in Brazil
- Nucleic acid medicine project for peritoneal dissemination
- Gene therapy project using RNA editing technology
- Drug discovery project using novel antibody modification technology
- Consideration of joint commercialization of functional fluorescent probe technology
| Item | Details |
|---|---|
| Document type | Supplementary materials to the earnings summary |
| Fiscal Period Covered | Third quarter of the fiscal year ending December 2026 |
| Net Sales | ¥346 million |
| Operating profit | ¥-676 million |
| Net income | ¥-680 million |
| Selling, general and administrative expenses | ¥511 million |
| Full-year earnings forecast | Product Sales Revenue ¥350 million / Cost of Product Sales ¥190 million / License Agreement Revenue Not disclosed / Total Sales Revenue Not disclosed |
| New initiatives | Transfer of the Sancuso® sales structure to MAAB Pharma Limited and product shipments, Initiatives focused on licensing Chinese manufacturing rights to MAAB and local production, Commencement of supply to Daiichi Sankyo Brasil for the sale of episil® in Brazil, Nucleic acid medicine project for peritoneal dissemination, Gene therapy project using RNA editing technology, Drug discovery project using novel antibody modification technology, Consideration of joint commercialization of functional fluorescent probe technology |
Items this document does not state (23)
Ordinary incomeGross Profit MarginOperating profit marginResults for the three months of the current quarterProgress against full-year forecastSelf-assessment against the planSegment resultsBreakdown of Factors Affecting the ChangeKey KPIsUnit price and quantity metricsNumber of stores and locationsNumber of employeesAssumptions Underlying the Business OutlookRisk amount incorporated into the outlookMedium-term management plan targetsFinancial targetsAnnual DividendPayout ratioAcquisition of treasury sharesCapital expendituresOrders received and order backlogMarket Size / ShareKey points of the Q&A
These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.
The reasons the company gives
The company's own explanation, not something inferred from the numbers.No reason was given for lowering the product sales revenue forecast. As for actual results, the company attributed revenue to product sales revenue from Sancuso® and episil®, revenue from the Sancuso® license agreement, and milestone revenue from episil® in Brazil.
How to read this page
This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.
Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.
Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.